Cybin’s (CYBN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Cybin (NYSEAMERICAN:CYBNFree Report) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

Separately, Cantor Fitzgerald reissued an overweight rating and issued a $3.00 price target on shares of Cybin in a research report on Tuesday.

Check Out Our Latest Report on Cybin

Cybin Price Performance

Shares of NYSEAMERICAN CYBN opened at $0.31 on Tuesday. The company has a market capitalization of $61.86 million, a P/E ratio of -1.63 and a beta of 1.47. Cybin has a 1 year low of $0.21 and a 1 year high of $1.14.

Cybin (NYSEAMERICAN:CYBNGet Free Report) last issued its quarterly earnings data on Tuesday, June 27th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Analysts forecast that Cybin will post -0.19 earnings per share for the current fiscal year.

About Cybin

(Get Free Report)

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in in preclinical stage to treat neuroinflammation.

Featured Articles

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with's FREE daily email newsletter.